Confirming SAP results with further test is the best way to diagnose VF abnormalities

Article

It is best to confirm visual field (VF) abnormality as shown by Standard Automated Perimetry (SAP) with either a further SAP test or a Short-Wavelength Automated Perimetry (SWAP) test, concluded a study published in the March 2009 issue of Investigative Ophthalmology and Visual Science.

It is best to confirm visual field (VF) abnormality as shown by Standard Automated Perimetry (SAP) with either a further SAP test or a Short-Wavelength Automated Perimetry (SWAP) test, concluded a study published in the March 2009 issue of Investigative Ophthalmology and Visual Science.

Professor Robert Weinreb of the Hamilton Glaucoma Center and Department of Ophthalmology, University of California at San Diego, US and colleagues evaluated data from glaucomatous (n=174) and healthy (n=164) eyes, each with reliable 24-2 SAP-SITA, SWAP-SITA and Matrix FDT tests. The researchers created three definitions of VF abnormality: single-test abnormality, abnormality as confirmed by repeating the same test, and abnormality as confirmed by conducting a second, different, test. Using these three abnormality definitions, the team assessed each test’s sensitivity, the agreement between tests, the deficit locations and machine-generated pattern standard deviation (PSD) to compare the testing methods.

Professor Weinreb’s team discovered that single tests of SAP, SWAP and FDT had sensitivities of 30%, 29% and 28%, respectively. When confirming the abnormality with the same test, sensitivities were 24–27%; when confirming with a different test, the sensitivity range was 20–23%. The sensitivities of the combinations of different tests were all lower than the SAP/SAP test, and the sensitivities of the same-tests were higher than that of the SWAP/FDT test.

Therefore the team concluded that it is important to confirm a diagnosis of VF abnormality on SAP by subsequently testing again, either with SAP or SWAP.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.